TorreyPines Therapeutics, Inc. Receives Notice of Delisting from Nasdaq Global Market
Published: Jul 21, 2009
LA JOLLA, Calif., July 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. announced today that it had received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that it did not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5450(b)(1)(A), prior to the expiration of the extension granted by the Staff on July 14, 2009. TorreyPines initially received notification from the Staff of its noncompliance with the minimum $10,000,000 stockholders' equity requirement for continued listing on March 31, 2009.
There can be no assurances that the Listing Qualifications Panel will grant the Company's request for continued listing on The Nasdaq Global Market, in which case the Company's common stock could be delisted from The Nasdaq Stock Market.
TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com.
SOURCE TorreyPines Therapeutics, Inc.
CONTACT: Paul Schneider of TorreyPines Therapeutics, Inc.,
+1-858-623-5665, ext. 125, pschneider@TPTXinc.com
Web site: http://www.tptxinc.com/